drugset
Drugs / Astegolimab
last change Jul 2025 re-read 2 minutes ago

Astegolimab

also known as MSTT1041A · AMG 282 · RG-6149 · RO-7187807

Monoclonal antibody

Developed for
chronic obstructive pulmonary disease · asthma · atopic eczema · chronic rhinosinusitis · pneumonia
Investigated by
Genentech, Inc. · Hoffmann-La Roche · Amgen · Biomedical Advanced Research and Development Authority · Glenfield Hospital, Leicester · University of Leicester

Trials 9 · a red edge is where a trial was stopped

today NCT06462118 · Ph 1 NCT05878769 · Ph 3 NCT05595642 · Ph 3 NCT05037929 · Ph 2 NCT04386616 · Ph 2 NCT03747575 · Ph 2 NCT03615040 · Ph 2 NCT02918019 · Ph 2 NCT02170337 · Ph 1
2014201520162017201820192020202120222023202420252026202720282029203020312032203320342035
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 12 trials
Phase 1 NCT06462118 Jun → Oct 2024 — Genentech, Inc. Completed No outcome recorded
Phase 1 NCT02170337 Jul 2014 → May 2016 chronic rhinosinusitis Amgen Completed No outcome recorded
Phase 25 trials
Phase 2 NCT05037929 Oct 2021 → Feb 2025 chronic obstructive pulmonary disease Genentech, Inc. Completed No outcome recorded
Phase 2 NCT04386616 Jun 2020 → Jan 2021 pneumonia Genentech, Inc. Completed No outcome recorded
Phase 2 NCT03747575 Feb 2019 → Mar 2020 atopic eczema Genentech, Inc. Completed No outcome recorded
Phase 2 NCT03615040 Oct 2018 → May 2020 chronic obstructive pulmonary disease University of Leicester Completed No outcome recorded
Phase 2 NCT02918019 Sep 2016 → Apr 2019 asthma Hoffmann-La Roche Completed No outcome recorded
Phase 32 trials
Phase 3 NCT05878769 Jun 2023 → Jul 2034 expected chronic obstructive pulmonary disease Hoffmann-La Roche Recruiting No outcome recorded
Phase 3 NCT05595642 Dec 2022 → Jun 2025 overdue chronic obstructive pulmonary disease Hoffmann-La Roche Active not recruiting No outcome recorded
Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT01928368 Comparator Aug 2013 → Mar 2016 asthma Amgen Completed No outcome recorded

Press releases naming this drug 1 release

DateIssuerRelease
2025-07-21 Roche Global Development [Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on astegolimab in chronic obstructive pulmonary disease roche.com ↗

Evidence & citations 9 cited values

Every value below carries the sentence it was read from. 12 sources stand behind the page.

FieldValueCited text
Known as astegolimab “This study will assess the efficacy and safety of MSTT1041A (astegolimab) in participants with moderate to severe atopic dermatitis (AD).” NCT03747575 ↗
4

NCT05595642 ↗

NCT05878769 ↗

NCT05037929 ↗

NCT06462118 ↗
Known as AMG 282 ClinicalTrials.gov intervention name — accepted as the source's own label NCT02170337 ↗
1

NCT01928368 ↗
Known as MSTT1041A ClinicalTrials.gov intervention name — accepted as the source's own label NCT03615040 ↗
3

NCT02918019 ↗

NCT04386616 ↗

NCT03747575 ↗
Known as RG-6149 ChEMBL registry synonym — accepted as the source's own label CHEMBL4594385 ↗
Known as RO-7187807 ChEMBL registry synonym — accepted as the source's own label CHEMBL4594385 ↗
Action Inhibit “a human immunoglobulin G2 monoclonal antibody that selectively inhibits the IL-33 receptor, ST2” PMID 36519984 ↗ Nov 2022
Modality Monoclonal antibody “a human immunoglobulin G2 monoclonal antibody that selectively inhibits the IL-33 receptor, ST2” PMID 36519984 ↗ Nov 2022
Route Intravenous “Single dose either subcutaneously or intravenously on day 1.” NCT01928368 ↗
Route Subcutaneous “Single dose either subcutaneously or intravenously on day 1.” NCT01928368 ↗